Pruritus Pipeline Analysis Demonstrates 27+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
11 janv. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Pruritus Pipeline Analysis Demonstrates 27+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight ...
American Kidney Fund’s New Campaign Focuses on Improving Quality of Life for People with Pruritus
21 juin 2022 09h00 HE
|
American Kidney Fund
ROCKVILLE, Md., June 21, 2022 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today launched a new education and awareness campaign that will raise awareness of pruritus and help people with...
American Kidney Fund Announces Support from Vifor Pharma for Pruritus Education Campaign
31 mars 2022 09h00 HE
|
American Kidney Fund
ROCKVILLE, Md., March 31, 2022 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced sponsorship from Vifor Pharma for an education and awareness campaign on chronic kidney...
Trevi Therapeutics Announces Second Quarter 2020 Financial Results and Business Update
13 août 2020 16h05 HE
|
Trevi Therapeutics
Announced Positive Outcome of Sample Size Re-Estimation Analysis for PRISM Trial Strong Enrollment in PRISM Trial After Lifting of COVID-19 Restrictions Announces $14 Million Term Loan - Cash...
Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) at 24th World Congress of Dermatology
10 juin 2019 09h05 HE
|
Sienna Biopharmaceuticals, Inc.
-- Phase 2b Trial Results Demonstrated SNA-120 Had Significant Impact on Psoriasis and Was Well-Tolerated WESTLAKE VILLAGE, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc....
Sienna Biopharmaceuticals Successfully Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis
24 juil. 2018 09h05 HE
|
Sienna Biopharmaceuticals, Inc.
-- SNA-120, a new chemical entity derived from the company’s Topical by Design™ platform, was well tolerated with minimal to no detectable systemic exposure -- Vast majority of psoriasis patients...
Sienna Biopharmaceuticals to Present SNA-125 Pre-Clinical Psoriasis Data as Late-Breaker at the International Investigative Dermatology Congress
16 mai 2018 09h05 HE
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that pre-clinical data from the Company’s topical product candidate SNA-125,...
Sienna Biopharmaceuticals Establishes Corporate Advisory Board
12 déc. 2017 09h05 HE
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the formation of a Corporate Advisory Board that will provide scientific,...
Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120
24 oct. 2017 09h05 HE
|
Sienna Biopharmaceuticals, Inc.
-- Trial to Enroll Approximately 190 Patients with Pruritus Associated with Psoriasis-- Top-Line Results Expected in First Half of 2019 WESTLAKE VILLAGE, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) --...